Sarcopenia Treatment Pipeline Expands with Over 18 Companies in Development
The clinical development pipeline for sarcopenia is expanding, with more than 18 companies actively developing new therapies. A report details over 20 drug candidates in various research stages.
New York – October 1, 2026 – The development of treatments for sarcopenia, an age-related loss of muscle mass, is expanding with over 18 companies actively engaged in therapeutic research. DelveInsight's "Sarcopenia Pipeline Insight 2026" report identifies more than 20 drug candidates progressing through various stages of clinical and preclinical development.
The report highlights ongoing research, including a Phase 1/2a study initiated by Unlimited Biotechnology LLC evaluating the safety and tolerability of AAV9-Follistatin gene therapy. Separately, Erasmus Medical Center is studying the effect of intradialytic parenteral nutrition (IDPN) on maintaining lean muscle mass in hemodialysis patients.
Key companies involved in the sarcopenia treatment landscape include Biophytis, Epirium Bio, and Turn Biotechnologies. Their respective drug candidates, such as Biophytis' BIO101 and Epirium Bio's MF-300, are advancing through clinical and preclinical trials.
Sarcopenia is a progressive condition characterized by the loss of skeletal muscle mass, strength, and function, primarily affecting older adults. The World Health Organization (WHO) recognizes sarcopenia as a distinct disease, and its impact on an aging global population underscores the need for effective treatments.
This expanding pipeline signifies a growing effort to address sarcopenia, a condition that significantly impacts mobility, quality of life, and overall health in the elderly population.